The Regenerative Medicine and Stem Cells Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the Regenerative medicine and Stem cells partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in regenerative medicine and stem cells deals
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for regenerative medicine and stem cells

The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine and stem cells partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors regenerative medicine and stem cells technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest regenerative medicine and stem cells agreements including cell therapy agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all regenerative medicine and stem cells partnering deals announced since 2009 including financial terms where available including over 650 links to online deal records as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What are the precise rights granted or optioned?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in regenerative medicine and stem cells dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading regenerative medicine and stem cells deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of regenerative medicine and stem cells deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of regenerative medicine and stem cells partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology type . Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in regenerative medicine and stem cells partnering and dealmaking since 2009.

In addition, a comprehensive appendix is provided organized by regenerative medicine and stem cells partnering company A-Z , deal type definitions and regenerative medicine and stem cells partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of regenerative medicine and stem cells technologies and products.

Regenerative Medicine and Stem Cells Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of regenerative medicine and stem cells deal trends since 2009
Access to headline, upfront, milestone and royalty data
Analysis of the structure of regenerative medicine and stem cells agreements with numerous real life case studies
Comprehensive access to over 1500 actual regenerative medicine and stem cells contracts entered into by the world’s biopharma companies
Detailed access to actual regenerative medicine and stem cells contracts enter into by the leading fifty bigpharma companies
Insight into the terms included in a regenerative medicine and stem cells agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in regenerative medicine and stem cells dealmaking

2.1. Introduction
2.2. Regenerative medicine and stem cells partnering over the years
2.3. Big pharma regenerative medicine and stem cells dealmaking activity
2.5. Most active in regenerative medicine and stem cells partnering
2.6. Regenerative medicine and stem cells partnering by deal type
2.7. Regenerative medicine and stem cells partnering by disease type
2.8. Partnering by regenerative medicine and stem cells technology type
2.9. Average deal terms for regenerative medicine and stem cells partnering
2.9.1 Regenerative medicine and stem cells headline values
2.9.2 Regenerative medicine and stem cells upfront payments
2.9.3 Regenerative medicine and stem cells milestone payments
2.9.4 Regenerative medicine and stem cells royalty rates
2.10. The anatomy of regenerative medicine and stem cells partnering
2.10. The anatomy of a regenerative medicine and stem cells deal
2.10.a. Case study 1: Oregon Health and Science University- Regen BioPharma- June 2012
2.10.b. Case study 2: Thermogenesis- Nanshan Memorial Medical Institute- November 2010
2.10.c. Case study 3: Ascent Therapeutics- Bioheart- January 2010

Chapter 3 - Leading regenerative medicine and stem cells deals

3.1. Introduction
3.2. Top regenerative medicine and stem cells deals by value

Chapter 4 - Big pharma regenerative medicine and stem cells deals

4.1. Introduction

4.2. How to use big pharma regenerative medicine and stem cells partnering deals

4.3. Big pharma regenerative medicine and stem cells partnering company profiles

Abbott
Astellas
AstraZeneca
Bayer
Boehringer Ingelheim
Dainippon Sumitomo
Eli Lilly
GlaxoSmithKline
Johnson and Johnson
Merck and Co
Merck KGaA
Novartis
Otsuka
Pfizer
Roche
Sanofi
Teva
UCB

Chapter 5 - Regenerative medicine and stem cells partnering contracts directory

5.1. Introduction

5.2. Company A-Z

5.3. By deal type

Asset purchase
Co-development
Collaborative RandD
Contract service
Co-promotion
Development
Distribution
Equity purchase
Licensing
Manufacturing
Marketing
Material transfer
Option
Research
Settlement
Sub-license
Technology transfer

5.4. By stage of development

Discovery
Marketed
Phase I
Phase II
Preclinical

5.5. By therapy area

Cardiovascular
Central Nervous System
Gastrointestinal
Genetic disorders
Hematology
Hospital care
Immunology
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Orphan disease
Respiratory

Chapter 6 - Regenerative medicine and stem cells dealmaking by technology type

6.1. Introduction
6.2. Deals by regenerative medicine, cell therapy, organ regeneration,tissue regenration and stem cells type
Regenerative medicine
Stem cells

Appendices

Introduction

Appendix 1 - Directory of regenerative medicine and stem cells deals by company A-Z 2009-2014

Appendix 2 - Directory of regenerative medicine and stem cells deals by stage of development 2009-2014

Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory

Appendix 3 - Directory of regenerative medicine and stem cells deals by deal type 2009-2014

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative RandD
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Interests
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty

Appendix 4 - Directory of regenerative medicine and stem cells deals by therapy area 2009-2014

Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Hematology
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Obstetrics
Oncology
Ophthalmics
Orphan disease
Pediatrics
Respiratory

Appendix 5 - Regenerative medicine and stem cells partnering resource center

Online regenerative medicine and stem cells partnering
Regenerative medicine and stem cells partnering events
Further reading on regenerative medicine and stem cells dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form - Reports

TABLE OF FIGURES

Figure 1: Regenerative medicine and stem cells partnering since 2009
Figure 2: Big pharma - top 50 - Regenerative medicine and stem cells deals 2009 to 2014
Figure 3: Big pharma regenerative medicine and stem cells deal frequency - 2009 to 2014
Figure 4: Active regenerative medicine and stem cells dealmaking activity- 2009 to 2014
Figure 5: Regenerative medicine and stem cells partnering by deal type since 2009
Figure 6: Regenerative medicine and stem cells partnering by disease type since 2009
Figure 7: Regenerative medicine and stem cells partnering by technology type since 2009
Figure 8: Regenerative medicine and stem cells deals with a headline value
Figure 9: Regenerative medicine and stem cells deal headline value distribution, US$million - discovery stage
Figure 10: Regenerative medicine and stem cells deal headline value distribution, US$million - preclinical stage
Figure 11: Regenerative medicine and stem cells deal headline value distribution, US$million - phase I stage
Figure 12: Regenerative medicine and stem cells deal headline value distribution, US$million - phase II stage
Figure 13: Regenerative medicine and stem cells deal headline value distribution, US$million - phase III stage
Figure 14: Regenerative medicine and stem cells deal headline value distribution, US$million - regulatory stage
Figure 15: Regenerative medicine and stem cells deal headline value distribution, US$million - marketed stage
Figure 16: Summary median headline value by stage of development, 2009-2014
Figure 17: Regenerative medicine and stem cells deals with upfront payment values
Figure 18: Regenerative medicine and stem cells deal upfront payment distribution, US$million - discovery stage
Figure 19: Regenerative medicine and stem cells deal upfront payment distribution, US$million - preclinical stage
Figure 20: Regenerative medicine and stem cells deal upfront payment distribution, US$million - phase I stage
Figure 21: Regenerative medicine and stem cells deal upfront payment distribution, US$million - phase II stage
Figure 22: Regenerative medicine and stem cells deal upfront payment distribution, US$million - phase III stage
Figure 23: Regenerative medicine and stem cells deal upfront payment distribution, US$million - regulatory stage
Figure 24: Regenerative medicine and stem cells deal upfront payment distribution, US$million - marketed stage
Figure 25: Summary median upfront payments by stage of development, 2009-2014
Figure 26: Regenerative medicine and stem cells deals with milestone payments
Figure 27: Regenerative medicine and stem cells deal milestone distribution, US$million - discovery stage
Figure 28: Regenerative medicine and stem cells deal milestone distribution, US$million - preclinical stage
Figure 29: Regenerative medicine and stem cells deal milestone distribution, US$million - phase I stage
Figure 30: Regenerative medicine and stem cells deal milestone distribution, US$million - phase II stage
Figure 31: Regenerative medicine and stem cells deal milestone distribution, US$million - phase III stage
Figure 32: Regenerative medicine and stem cells deal milestone distribution, US$million - regulatory stage
Figure 33: Regenerative medicine and stem cells deal milestone distribution, US$million - marketed stage
Figure 34: Regenerative medicine and stem cells deals with royalty rates, %
Figure 35: Regenerative medicine and stem cells deal royalty rate distribution, US$million - discovery stage
Figure 36: Regenerative medicine and stem cells deal royalty rate distribution, US$million - preclinical stage
Figure 37: Regenerative medicine and stem cells deal royalty rate distribution, US$million - phase I stage
Figure 38: Regenerative medicine and stem cells deal royalty rate distribution, US$million - phase II stage
Figure 39: Regenerative medicine and stem cells deal royalty rate distribution, US$million - phase III stage
Figure 40: Regenerative medicine and stem cells deal royalty rate distribution, US$million - regulatory stage
Figure 41: Regenerative medicine and stem cells deal royalty rate distribution, US$million - marketed stage
Figure 42: Summary median royalty rate by stage of development, 2009-2014
Figure 43: Components of the typical regenerative medicine and stem cells deal structure
Figure 44: Top regenerative medicine and stem cells deals by value since 2009
Figure 45: Online partnering resources
Figure 46: Forthcoming partnering events

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Analytical Tool - Cancer Immunotherapy

Analytical Tool - Cancer Immunotherapy

  • $ 8 175
  • Industry report
  • March 2014
  • by Bioseeker

"Analytical Tool- Cancer Immunotherapy" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in immunotherapy drug development for the treatment of cancer. It ...

Stem Cells -- 6 Dimensional Assessment (Technical Insights)

Stem Cells -- 6 Dimensional Assessment (Technical Insights)

  • $ 6 500
  • Industry report
  • June 2014
  • by Frost & Sullivan

The clinical translation of regenerative cells The scope of this research service comprises research within the area of adult and embryonic stem cells, and developments in the nascent area of induced pluripotent ...

The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus

The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus

  • $ 4 995
  • Industry report
  • June 2014
  • by Firstword Pharma

There has been considerable media hype and clinical interest in cancer immunotherapy in recent years. Indeed, there is talk of late stage cancers such as melanoma and NSCLC being managed as chronic conditions ...

Global Brachytherapy Market

April 2014 $ 4 500

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.